FDA panel recommends approval of transplant drug belatacept

03/1/2010 | Reuters

An FDA panel voted 13-5 to endorse the approval of Bristol-Myers Squibb's belatacept for use in preventing kidney transplant rejection and maintaining organ function in end-stage renal disease. However, advisers recommended that the company establish a patient registry and conduct follow-up studies for at least three years to track the drug's long-term effects.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC